For the Inventor, By the Inventor

Enter assignee name

Rochester, NY, United States of America

Vaccinex, Inc.

USPTO Granted Patents = 53

% Expired Patents = 11.3

CIPO Patents = 7

EPO Patents = 24

Trademarks = 1

Forward Citations = 373

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Ernest S Smith (44 out of 47 patents)

Maurice Zauderer (28 out of 41 patents)

Mark Paris (13 out of 13 patents)

4. Elizabeth E Evans (11 out of 19 patents)

5. Terrence Lee Fisher (9 out of 19 patents)

6. Renee A Kirk (8 out of 8 patents)

7. Angelica A Cornelison (7 out of 7 patents)

8. Maria G M Scrivens (6 out of 6 patents)

9. William J Bowers (4 out of 9 patents)

10. Alan Jonason (4 out of 4 patents)

11. Leslie A Balch (4 out of 4 patents)

12. Leslie A Croy (4 out of 4 patents)

13. Maria Scrivens (4 out of 4 patents)

14. Ekaterina Klimatcheva (3 out of 3 patents)

15. Tracy Pandina (3 out of 3 patents)

Core Competencies:

Semaphorin-4D

Anti-CD100 Antibodies

CXCL13 Antibodies

Immune Modulating Therapy

Neurodegenerative Disorders

Poxvirus Extracellular Virions

Polynucleotide Libraries

Tumor Growth Inhibition

Atherosclerosis Treatment

NKT Cell Modulation

Epigenetic Modulating Agents

Monoclonal Antibodies

53 patents: Sort by Forward Citations

1. 12668630 - HUMAN ANTI-SEMAPHORIN 4D ANTIBODY (2026-06-30),

2. 12496342 - Anti-CCR8 Antibodies and Uses Thereof (2025-12-16),

3. 12201719 - Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy (2025-01-21),

4. 12070500 - Use of semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastasis (2024-08-27),

5. 12006365 - Human anti-semaphorin 4D antibody (2024-06-11),

6. 12006364 - Anti-CD100 antibodies and methods for using the same (2024-06-11),

7. 11981730 - Anti-CXCL13 antibodies and methods of using the same (2024-05-14),

8. 11976383 - Integral membrane protein display on poxvirus extracellular enveloped virions (2024-05-07),

9. 11859000 - Anti-CCR8 antibodies and uses thereof (2024-01-02),

10. 11660330 - Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy (2023-05-30),

11. 11597765 - Use of semaphorin-4D binding molecules for the treatment of Rett syndrome (2023-03-07),

12. 11572408 - Treatment of cancer with a semaphorin-4D antibody in combination with an epigenetic modulating agent (2023-02-07),

13. 11534488 - Use of semaphorin-4D binding molecules for modulation of blood brain barrier permeability (2022-12-27),

14. 11427634 - Human anti-semaphorin 4D antibody (2022-08-30),

15. 11274149 - Anti-CD100 antibodies and methods for using the same (2022-03-15),

Vaccinex, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel therapeutic antibodies to treat a wide range of diseases, including cancer and neurodegenerative disorders. With its proprietary platform called ActivMAb®, Vaccinex discovers and optimizes fully human antibodies with unique mechanisms of action. The company is dedicated to improving patient outcomes by advancing its pipeline of therapeutic candidates through rigorous scientific research and clinical trials.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

53 Patents

#20 in Rochester, NY

#407 in New York

#6,661 in US

#13,309 in the World

Rochester, NY, United States of America

Vaccinex, Inc.

Forward Citations = 373

40 inventors:

Ernest S Smith (44 out of 47 patents)

Maurice Zauderer (28 out of 41 patents)

Mark Paris (13 out of 13 patents)

4. Elizabeth E Evans (11 out of 19 patents)

5. Terrence Lee Fisher (9 out of 19 patents)

Please report any incorrect information to [email protected]

Loading…